End-Stage Renal Disease (ESRD)Symptoms, Doctors, Treatments, Advances & More
Learn About End-Stage Renal Disease (ESRD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory University Hospital Midtown Campus
Janice Lea is a Nephrologist practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 38 years. Dr. Lea is rated as an Elite provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Renovascular Hypertension, Nephrosclerosis, and Kidney Transplant. Dr. Lea is board certified in American Board Of Internal Medicine, 1994.
East Tennessee Medical Associates, P.C.
Lara Kfoury is a Nephrologist practicing medicine in Johnson City, Tennessee. Dr. Kfoury is rated as a Distinguished provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Acute Kidney Failure, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, and Nephrosclerosis. Dr. Kfoury is board certified in American Board Of Internal Medicine.
Bassett Medical Center
Eric Knight is a Nephrologist practicing medicine in Cooperstown, New York. Dr. Knight is rated as a Distinguished provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Pseudohypoaldosteronism Type 2, and Liddle Syndrome.
Summary: Atrial fibrillation is the most frequent cardiac rhythm disorder and its prognosis is essentially marked by the risk of embolic events. Its treatment is based on long-term oral anticoagulant therapy according to the risk of embolic events assessed by risk scores such as the CHA2DS2-Vasc score, but this prescription is associated with a risk of hemorrhagic events that must be taken into considerati...
Summary: The goal of this clinical trial is to learn if Coated Aldehyde Oxystarch (Xiqing) works to reduce protein-bound uremic toxins (PBUTs) in adults with end-stage renal disease (ESRD). It will also learn about the safety of Coated Aldehyde Oxystarch. The main questions it aims to answer are: Does Coated Aldehyde Oxystarch lower the blood levels of protein-bound uremic toxins, such as indoxyl sulfate a...